What's in Hansoh BioMedical R&D Company's pipeline?

Hansoh BioMedical R&D Company has 17 drugs in our index: 1 marketed, 0 filed, 6 in Phase 3, 4 in Phase 2, 6 in Phase 1.

Which companies overlap with Hansoh BioMedical R&D Company's portfolio?

Top competitors by shared drug class: Bayer, Beta Pharma Shanghai, Betta Pharmaceuticals Co., Ltd., Brigham and Women's Hospital, Caliway Biopharmaceuticals Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/hansoh-biomedical-r-d-company.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Hansoh BioMedical R&D Company — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hansoh BioMedical R&D Company pipeline: 1 marketed, 0 filed, 6 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 6 Phase 3 4 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Drospirenone and Ethinyl Estradiol tablets	Drospirenone and Ethinyl Estradiol tablets	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor	Contraception / Gynecology
HS-20093	HS-20093	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)	Oncology
HS-10374-matched placebo tablets	HS-10374-matched placebo tablets	phase 3
Placebo&HS-20137	Placebo&HS-20137	phase 3
HS-20089	HS-20089	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)	Oncology
Gemcitabine combined with docetaxel	Gemcitabine combined with docetaxel	phase 3	Chemotherapy combination (nucleoside analog + taxane)	Ribonucleotide reductase (gemcitabine); β-tubulin/microtubules (docetaxel)	Oncology
HS-20137	HS-20137	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)	Oncology

Therapeutic area mix

Oncology · 4
Contraception / Gynecology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Bayer · 1 shared drug class
Beta Pharma Shanghai · 1 shared drug class
Betta Pharmaceuticals Co., Ltd. · 1 shared drug class
Brigham and Women's Hospital · 1 shared drug class
Caliway Biopharmaceuticals Co., Ltd. · 1 shared drug class
Central European Cooperative Oncology Group · 1 shared drug class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
Allist Pharmaceuticals, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Hansoh BioMedical R&D Company:

Cite this brief

Drug Landscape (2026). Hansoh BioMedical R&D Company — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hansoh-biomedical-r-d-company. Accessed 2026-05-17.